Skip to main content

Table 3 Relationship between rs9939609 polymorphism and virologic responses to HCV treatment in HIV/HCV-coinfected patients according to HCV genotypes

From: FTOrs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients

HCV genotype All patients TT AT AA P-value(a) aOR (95%CI) P-value(b)
All patients 55.1% (98/178) 64.3% (45/70) 51.8% (43/83) 40.0% (10/25) 0.026 0.58 (0.34; 0.99) 0.044
GT2/3 patients 85.5% (47/55) 92.0% (23/25) 83.3% (20/24) 66.7% (4/6) 0.125 0.43 (0.14; 1.31) 0.138
GT1/4 patients 40.7% (48/118) 48.8% (20/41) 37.9% (22/58) 31.5% (6/19) 0.171 0.59 (0.31; 1.12) 0.105
  1. a P-values were calculated by linear-by-linear association Chi-squared test; b P-values were calculated by multivariate generalized linear models (GLM) adjusted by the most important clinical and epidemiological characteristics (see Statistical analysis section). Statistically significant differences are shown in bold. 95%CI, 95% confidence interval; aOR, adjusted odds ratio; GT1/4, HCV genotype 1/4; GT2/3, HCV genotype 2/3; HCV, hepatitis C virus; HIV, human immunodeficiency virus; SVR, sustained virologic response.